[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"biomarker\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:biomarker":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,52,83,121,144,175,201,223,248,272,298,322,347,370,401,425],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100467853","tennessee-alzheimers-project-100467853",false,"NCT05372172","Tennessee Alzheimer's Project","TAP","Inclusion Criteria:\n\n* Age 60 or older\n* Meet standard criteria for (a) cognitively unimpaired, (b) mild cognitive impairment, or (c) Alzheimer's disease\n* English speaking\n* Individuals who lack decisional capacity to provide informed consent at baseline will not be enrolled in the study\n\nExclusion Criteria:\n\n* No available reliable study partner (reliable is defined as someone who interacts significantly with the participant and is available to participate in study visits in person or by phone)\n* History of major psychiatric illness (e.g., schizophrenia, bipolar), neurological illness (e.g., epilepsy, multiple sclerosis, Parkinson's disease), or head injury with significant loss of consciousness.\n* Unable to undergo MRI (e.g., claustrophobia, ferrous metal in body)",true,"ALL","60 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","The primary objective of the Vanderbilt Alzheimer's Disease Research Center (VADRC) is to provide local and national researchers with access to a well-characterized and diverse clinical cohort, including participant referrals, biosamples, clinical data, and neuroimaging data. The VADRC Clinical Core will create an infrastructure to support research efforts of both local and national investigator studies to develop early detection, prevention, and treatment strategies for Alzheimer's disease. The Clinical Core intends to enroll up to 1000 participants, including individuals who are cognitively unimpaired, have mild cognitive impairment, or have Alzheimer's disease. This cohort of about 1000 participants will be called the Tennessee Alzheimer's Project. Participants will be seen annually for comprehensive clinical characterization and then referred to other studies to enhance Alzheimer's disease research activities.",[25,26,27,28,29,30,31],"Aging","Alzheimer Disease","Biomarker","Cognitive Dysfunction","Mild Cognitive Impairment","Dementia","Cognition",[33,34,35,36,37,38],"Alzheimer's disease","biomarkers","brain MRI","mild cognitive impairment","vascular risk factors","longitudinal studies","RECRUITING","2026-02-02",{"date":42,"type":43},"2026-02-05","ACTUAL",{"date":45,"type":43},"2021-10-27",{"date":47,"type":21},"2030-03-31",{"name":49,"class":50},"Vanderbilt University Medical Center","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":51},"100608613","diagnostic-and-prognostic-evaluation-of-vasorin-during-septic-shock-100608613","NCT07203833","Diagnostic and Prognostic Evaluation of Vasorin During Septic Shock","VASO-DIAG","Inclusion Criteria:\n\n* Adults over 18 years.\n* Patients admitted for less than 24 hours in intensive care unit of the CHU Amiens Picardie.\n* Group 1: patients with septic shock defined by sepsis with 2 mmol\u002Fl Lactates, requiring vasopressors to maintain mean blood pressure at 65 mmHg (despite adequate vascular filling) in the presence of fever (T°\\>38.3) with a documented or suspected infection\n* Group 2: patients with a shock defined by arterial hypotension requiring the use of vasopressors with 2 mmol\u002Fl Lactates but without suspected infection and apyrexie (T°\\\u003C38°). For example: vasoplegia post cardiac surgery with CBP or cardiogenic shock or hemorrhagic shock\n\nExclusion Criteria:\n\n* Pregnant women\n* Group 1 : No evidence of suspected or documented infection\n* Group 2 : Presence of fever and\u002For suspected infection","18 Years",{"count":61,"type":21},144,"INTERVENTIONAL",[64],"NA","Septic shock is the most severe form of infection. Currently, an early specific biomarker for septic shock is needed. Remember that shock situations are numerous, not only septic (eg hemorrhagic, cardiogenic...), and also accompanied by a severe pro-inflammatory state that it is sometimes difficult to distinguish from a septic state. Procalcitonin (PCT) is the most studied biomarker but still lacks sensitivity (77%) and specificity (79%). The investigators hypothesize that the Vasn could become this potential new biomarker and would allow a better diagnosis and thus the need or not to treat patients with antibiotics. The laboratory studies suggest a link between Vasn and septic shock. The goal of this project is to measure and compare plasma Vasn concentrations in 2 groups of patients = group 1: septic shock versus group 2: non-septic shock. Briefly, shock is defined as low blood pressure requiring vasopressor agents with confirmed infection (group 1) or without suspected infection such as patients admitted in intensive care unit post cardiac surgery with CBP (group 2). The investigators will also assess patient 28-day mortality to identify Vasn as a potential prognostic biomarker.",[67,68,69,27,70],"Vasorin","Septic Shock","Shock","Infection",[72,73,69,27,70],"Septic shock","vasorin","2026-01-06",{"date":76,"type":43},"2026-01-07",{"date":78,"type":43},"2025-10-19",{"date":80,"type":21},"2027-05",{"name":82,"class":50},"Centre Hospitalier Universitaire, Amiens",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":93,"conditions":94,"keywords":105,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":51},"100605647","association-of-pocd-with-circulating-biomarkers-in-patients-undergoing-tur-of-bladder-tumor-100605647","NCT07165236","Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor","Association of Perioperative Cognitive Dysfunction With Circulating Biomarkers of Neurological Damage in Patients Underging Transurethral Resection of Bladder Tumor","Inclusion Criteria:\n\n* adult patients from 18-80 years,\n* elective operations of tumor bladder cancer (TUR),\n* patients can communicate,\n* patients who can sign the information consent and questionnaires\n\nExclusion Criteria:\n\n* patients under the age of 18,\n* patients above 80 years,\n* patients who are unable to communicate\n* patients who do not understand informed consent for the research,\n* patients who are unable to write\n* emergency surgery,\n* patients with proven hypersensitivity to some of the drugs used in the study\n* patients in a state of shock, septic, or hemorrhagic patients with neurodevelopmental disorders","80 Years",{"count":92,"type":21},42,"Bladder tumor is one of the most widespread tumors in the world, with increasing prevalence at the global level. One of the procedures in patients with bladder tumors is transurethral resection of the bladder (TURM) most often performed endoscopically under general anesthesia. This patient population has certain characteristics in common. One of them is exposure to common risk factors for the formation of bladder tumors, such as aniline dyes and solvents. These substances are associated with the onset of neurodegeneration and oxidative stress. Smoking is another factor that affects the formation of bladder tumor. A significant part of patients with bladder tumor are an elderly population, which is repeatedly exposed to surgical procedures, with numerous comorbidities, with a high risk of postoperative complications and the development of perioperative cognitive deficits, which can further complicate the postoperative course and further treatment. In the group of patients with a bladder tumor who will undergo TURM, no evaluation of risk factors related to perioperative cognitive deficit was performed, nor was there an examination of the perioperative cognitive deficit itself. In them, the identification of factors for postoperative cognitive disorder is essential. The concept of clinical frailty is becoming more important and relevant when providing healthcare services to patients. The use of the clinical frailty scale as a tool in clinical practice provides information on the adequate direction of care for patients. Decrease in muscle strength can lead to limitations in the functioning of a certain individuals. In recent years muscle strength has come to be a very important component of health, regardless of a person's age and clinical condition.The hand grip test is a test used to measure the maximum isometric strength of the hand and forearm muscles. The MMSE test and MoCA are the most frequently used methods in the detection of cognitive impairment in clinical and research fields. In addition to laboratory indicators of organic function, circulating indicators of neuroinflammation, like S100B and neuron-specific enolase, will be correlated with the patient's cognitive status.So far, no research has been conducted on the dynamics of indicators of organic function, circulating indicators of neuroinflammation, perioperative cognitive changes and clinical fraility in patients undergoing bladder tumor operation.",[95,96,97,27,98,99,100,101,102,103,104],"Cognitive Decline","Urinary Bladder Cancer","Frail","General Anesthesia","Hand Grip Strength","Cognitive Testing","Comorbidities","Demographic Data","Socio-economic Status","Perioperative Complications",[106,107,108,109,110,111],"general anesthesia","postoperative cognitive complications","urinary bladder neoplasm","perioperative period","frail older adult","S100b","2025-09-02",{"date":114,"type":43},"2025-09-10",{"date":116,"type":43},"2024-11-28",{"date":118,"type":21},"2029-10-01",{"name":120,"class":50},"Osijek University Hospital",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":128,"targetDuration":130,"studyType":22,"phases":4,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":51},"100599775","novel-biomarkers-and-postoperative-kidney-injury-in-radical-nephrectomy-100599775","NCT07088874","Novel Biomarkers and Postoperative Kidney Injury in Radical Nephrectomy","Novel Biomarkers to Predict Acute Kidney Injury and Chronic Kidney Disease After Radical Nephrectomy: an Exploratory Prospective Cohort Study","Inclusion Criteria:\n\n* Age ≥18 years;\n* Scheduled to undergo unilateral radical nephrectomy.\n\nExclusion Criteria:\n\n* Solitary kidney;\n* Preoperative diagnosis of chronic kidney disease stages G4 or G5 (GFR \\\u003C30 mL\u002Fmin\u002F1.73m²);\n* Tumor invasion of the vena cava requiring thrombectomy;\n* Other conditions deemed by the investigator as unsuitable for participation in this study.",{"count":129,"type":21},60,"1 Year","The incidence of acute kidney injury (AKI) after radical nephrectomy exceeds 40%. Currently, the KDIGO criteria are the recognized diagnostic standard for AKI. These criteria primarily use serum creatinine and urine output as key indicators, but both parameters have certain limitations, such as delayed response, insensitivity, and inaccuracy. This study aims to simultaneously monitor perioperative novel renal damaging, stressful, and functional biomarkers in patients undergoing radical nephrectomy, and to investigate their predictive value for AKI and postoperative 1-year chronic kidney disease (CKD).",[133,134,27],"Nephrectomy","Acute Kidney Injury","2025-08-31",{"date":137,"type":43},"2025-09-08",{"date":139,"type":43},"2025-08-02",{"date":141,"type":21},"2027-07-30",{"name":143,"class":50},"Peking University First Hospital",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":152,"enrollmentInfo":153,"targetDuration":155,"studyType":22,"phases":4,"briefSummary":156,"conditions":157,"keywords":161,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":51},"100601498","dynamic-uc-early-qfit-and-calprotectin-change-predicting-relapse-in-biologic-naive-ulcerative-colitis-100601498","NCT07111273","DYNAMIC-UC: Early qFIT and Calprotectin Change Predicting Relapse in Biologic-Naive Ulcerative Colitis","Diagnostic Value of Quantitative Fecal Immunochemical Test (qFIT) and Calprotectin (FC) Dynamic Changes at 2 Weeks for Predicting 52-Week Relapse or Treatment Escalation in Biologic-Naive Ulcerative Colitis: A Multicenter, Prospective Cohort Study (DYNAMIC-UC)","DYNAMIC-UC","Inclusion Criteria:\n\n* Age 18-75 years.\n* Established diagnosis of Ulcerative Colitis (UC) confirmed by clinical, endoscopic, and histopathological criteria.\n* Endoscopic disease activity (Mayo Endoscopic Subscore ≥ 2) confirmed by colonoscopy during screening.\n* Biologic-naive (no prior exposure to any biologic agent \\[e.g., infliximab, adalimumab, vedolizumab, ustekinumab\\] or JAK inhibitor).\n* No use of systemic corticosteroids (oral or intravenous) within 4 weeks prior to Baseline (Week 0) visit.\n* If using oral or rectal mesalazine\u002F5-ASA preparations, dose must have been stable for ≥2 weeks prior to Baseline (Week 0).\n\nWilling and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Diagnosis or high suspicion of Crohn's disease, ischemic colitis, infectious colitis, radiation colitis, intestinal tuberculosis, or other types of colitis.\n\nPresence of other conditions clearly causing intestinal bleeding (e.g., acute hemorrhoidal bleeding, colorectal cancer, large colorectal polyps \\>1cm, intestinal vascular malformations).\n\n* Untreated systemic conditions that may cause intestinal bleeding (e.g., thrombocytopenia \\[PLT \\\u003C50 x 10\\^9\u002FL\\], severe coagulopathy).\n* Regular use of antiplatelet agents (e.g., aspirin, clopidogrel) or anticoagulants (e.g., warfarin, rivaroxaban).\n* Pregnancy or lactation.\n* Any other condition deemed by the investigator to make the patient unsuitable for study participation.","75 Years",{"count":154,"type":21},100,"14 Weeks","This multicenter prospective cohort study aims to evaluate whether a \\>50% decrease or normalization of both quantitative fecal immunochemical test (qFIT) and fecal calprotectin (FC) levels at 2 weeks after starting conventional therapy (mesalazine or corticosteroids) can predict clinical relapse or need for biologic\u002FJAK inhibitor therapy escalation by 52 weeks in biologic-naive patients with active ulcerative colitis (UC). Secondary objectives include assessing predictive value at 4 weeks, building dynamic prediction models, conducting health economic evaluation (Number Needed to Test, NNT), and exploring baseline predictors of early biomarker response. Patients will be observed during standard care with stool samples collected at Weeks 0, 2, and 4. Biomarker results will be blinded to clinicians\u002Fpatients until study completion.",[158,159,160,27],"Ulcerative Colitis (UC)","Fecal Calprotetin","FIT",[162,163,160,164],"ulcerative colitis","fecal calprotectin","biologic-naive","NOT_YET_RECRUITING","2025-08-06",{"date":168,"type":43},"2025-08-08",{"date":170,"type":21},"2025-08-01",{"date":172,"type":21},"2026-12-30",{"name":174,"class":50},"Qilu Hospital of Shandong University",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":184,"conditions":185,"keywords":188,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":200},"100598453","study-of-peripheral-blood-chi3l1-to-predict-tumor-response-to-radiotherapy-100598453","NCT07071688","Study of Peripheral Blood CHI3L1 to Predict Tumor Response to Radiotherapy","Predictive Value of Peripheral Blood CHI3L1 for Tumor Radiosensitivity: A Prospective and Retrospective Cohort Study","Inclusion Criteria:\n\n* Voluntarily signed informed consent form;\n* Age ≥ 18 years;\n* No restrictions on sex;\n* Histologically confirmed diagnosis of one of the following malignant tumors: nasopharyngeal carcinoma, head and neck cancer, lung cancer, breast cancer, gastric cancer, colorectal cancer, glioma, esophageal cancer, liver cancer, cholangiocarcinoma, cervical cancer, prostate cancer, or bladder cancer;\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n\nExclusion Criteria:\n\n* Patients with any serious comorbidities that may pose an unacceptable risk or adversely affect compliance with the study protocol. Examples include unstable heart disease requiring treatment, chronic hepatitis, renal disease with poor clinical status, uncontrolled diabetes mellitus (fasting blood glucose \\> 1.5 × ULN), or psychiatric disorders.\n* Deemed unsuitable for participation in the study at the discretion of the investigators.",{"count":183,"type":21},338,"Radiotherapy is an important treatment for many malignant tumors. However, radioresistance remains a major cause of treatment failure, often leading to tumor recurrence or progression. As a key factor affecting prognosis, radioresistance currently lacks reliable methods for identifying high-risk individuals before treatment. Liquid biopsy, as a non-invasive and dynamic monitoring tool, offers unique advantages for real-time assessment. Previous studies from our group have shown that peripheral blood levels of CHI3L1 are significantly elevated in patients with radioresistant tumors and may serve as a predictive biomarker for radiotherapy sensitivity. This study aims to conduct a multicenter, bidirectional cohort study to systematically evaluate the predictive value of peripheral blood CHI3L1 as a pan-cancer biomarker for tumor response to radiotherapy.",[186,187,27],"Tumor","Radiotherapy",[186,187,189,190],"Radioresistance","CHI3L1","2025-07-08",{"date":193,"type":43},"2025-07-17",{"date":195,"type":21},"2025-07-20",{"date":197,"type":21},"2028-12-31",{"name":199,"class":50},"Nanfang Hospital, Southern Medical University",3,{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":207,"minAge":59,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":4},"100566027","customized-circulating-tumor-dna-testing-for-cervical-cancer-recurrence-surveillance-and-treatment-decisions-100566027","NCT06649838","Customized Circulating Tumor DNA Testing for Cervical Cancer Recurrence Surveillance and Treatment Decisions","Inclusion Criteria:\n\n1. be willing and able to provide written informed consent\u002Fconsent for the trial.\n2. Be 18 years of age or older on the date of signing the informed consent form.\n3. patients with histologically or cytologically documented locally advanced, advanced, or first recurrent cervical cancer. For treatment-naive patients, 4) no previous cancer treatment including chemotherapy or radiotherapy; Patients with an initial recurrence had not received any other cancer treatment, including chemotherapy or radiotherapy, after the diagnosis of an initial recurrence before enrollment.\n\n5\\) measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\n\n6\\) willing and able to provide tumor lesions or excisional biopsy tissue. 7) a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale. Demonstrate adequate organ function.\n\n8\\) a negative pregnancy test in a fertile female patient.\n\nExclusion Criteria:\n\n1. be diagnosed as immunocompromised or receiving systemic steroid therapy or any other form of immunosuppressive therapy.\n2. a known history of active tuberculosis (Mycobacterium tuberculosis).\n3. have a known other malignancy that is progressing or requires active treatment.\n4. known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis.\n5. have an active autoimmune disease requiring systemic treatment within the past 2 years.\n6. known history or any evidence of active noninfectious pneumonia.\n7. active infection requiring systemic therapy.\n8. there is historical or current evidence of any condition, treatment, or laboratory abnormality that could confound the trial results, interfere with the patient's participation throughout the trial, or that the treatment investigator believes participation would not be in the patient's best interest.\n9. psychiatric or substance abuse disorders known to interfere with compliance with trial requirements.\n10. be pregnant or breastfeeding, or expect to become pregnant or give birth to a child within the intended duration of the trial.\n11. had a known history of human immunovirus (HIV) (HIV 1\u002F2 antibodies).\n12. known to have active hepatitis B (e.g., HBsAg reactive) or hepatitis C.\n13. received live vaccine within 30 days of planned initiation of study treatment.","FEMALE",{"count":129,"type":21},"Immunotherapy is the main option for advanced, recurrent and metastatic cervical cancer. However, due to the complex interaction between the immune system and tumors, there is still a lack of effective markers for immunotherapy. Scientists are actively searching for and developing new immunotherapy markers. For cervical cancer diagnosis, it has been shown that ctDNA mutations can reflect HPV integration sites. In terms of cervical cancer prognosis monitoring, cohort studies focused on the application of HPV ctDNA in the field of cervical cancer prognosis monitoring. The aim of this study is to design a customized ctDNA probe for cancer patients through a priori tumor detection method, and to guide recurrence monitoring plan and implement individualized adjuvant therapy according to the results, and to explore personalized biomarkers to guide cervical cancer immunotherapy. To explore the possibility of customized ctDNA detection as a diagnostic marker for cervical cancer. To explore the predictive and prognostic value of customized ctDNA dynamic monitoring. A multi-arm cohort clinical study is planned. To comprehensively study the treatment strategy of advanced and recurrent cervical cancer and explore the related biomarkers through the customized dynamic monitoring of ctDNA in patients with advanced and recurrent cervical cancer. A total of 60 patients with cervical cancer were enrolled.",[211,212,213,27],"Immunotherapy","Cervical Cancer","CtDNA","2024-12-16",{"date":216,"type":43},"2024-12-19",{"date":218,"type":21},"2024-12-20",{"date":220,"type":21},"2026-10-02",{"name":222,"class":50},"Peking Union Medical College Hospital",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":16,"sex":17,"minAge":59,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":62,"phases":232,"briefSummary":233,"conditions":234,"keywords":237,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":51},"100551187","comparative-evaluation-of-change-in-bite-force-and-levels-of-bone-turnover-markers-ctx-and-balp-in-hyperdivergent-and-hypodivergent-cases-during-retention-phases-a-prospective-clinical-trial--100551187","NCT06456827","''Comparative Evaluation of Change in Bite Force and Levels of Bone Turnover Markers CTX and BALP in Hyperdivergent and Hypodivergent Cases During Retention Phases-A Prospective Clinical Trial ''","Inclusion Criteria:\n\n* Non - growing (18-25) patients who had finished Fixed orthodontic cases ( ready for debonding )with FMA of 26 or more for hyperdivergent cases and FMA of 24 or less for hypodivergent cases\n* Optimal functional occlusion at end of treatment (PAR score \\>70%).\n* Littles irregularity index (Pre-treatment \\\u003C6mm in both upper and lower arch).\n* Nonsurgical and non-orthopedic patients and non syndromic patients.\n* Optimal periodontal condition and Good oral hygiene (probing depth \\\u003C3mm, gingival index score \\\u003C1\n* Good compliance regarding retainer wear\n\nExclusion Criteria:\n\n* Subjects with incomplete orthodontic treatment.\n* TMJ disorder patients.\n* Any systemic disease affecting bone and general growth.\n* Patients with incomplete records.\n* Patient who fail to follow up or undergo complete treatment.\n* Patient with learning difficulties\n* Patients having antibiotic therapy within previous 3 months and used anti -inflammatory drugs in the month before the study","45 Years",{"count":231,"type":21},40,[64],"Long-term studies have shown that various occlusal changes occur after the active phase of orthodontic treatment. some of these changes are unwanted changes and are considered as relapse The retention appliances are used to maintain the arch dimensions and alignment of the teeth after completion of the orthodontic treatment. One indicator of the functional state and health of the masticatory system is maximum voluntary bite force (MVBF). Its values vary in accordance to the location of measurement (highest at the first molar, lower at the incisors). People with pronounced horizontal craniofacial growth have somewhat higher values of MVBF, and those with vertical growth have lower values than do those with an average growth pattern. Clinical case reports and descriptive histologic data exist suggesting that bone and tooth remodeling persist for extended periods after removal of appliance or deactivation. A reflection of bone remodelling can be found in the gingival crevicular fluid (GCF) of moving teeth, with decrease or increase in the concentration of biomarker. This prompted us to evaluate the expression of variation in bone turnover marker levels (CTX-Bone resorption marker and BALP -Bone formation marker ) during the retention period. The International Osteoporosis Foundation (IOF) and International Federation of Clinical Chemistry (IFCC) have recommended C-terminal telopeptide of type I collagen (CTX) as one of the reference for BTMs. Hence, The present trial will be undertaken to assess the changes and compare if there is any difference in bite force and change in level of bone biomarker biomarker CTX type 1 collagen(C-terminal telopeptide of type I collagen and bone specific alkaline phosphatase(BALP) in post orthodontic treatment hypodivergent and hyperdivergent cases using beggs retainer over 12 months of period of retention.",[235,236,27],"Relapse","Bite Force",[238],"CTX and BALP biomarker , Bite force","2024-12-05",{"date":241,"type":43},"2024-12-10",{"date":243,"type":21},"2024-12-25",{"date":245,"type":21},"2026-08",{"name":247,"class":50},"Postgraduate Institute of Dental Sciences Rohtak",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":16,"sex":207,"minAge":59,"maxAge":229,"enrollmentInfo":255,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":51},"100523521","the-correlation-between-ovarian-function-and-serum-biomarkers-100523521","NCT06096766","The Correlation Between Ovarian Function and Serum Biomarkers","Study on the Correlation Between Ovarian Function and Serum Biomarkers","Inclusion Criteria:\n\n1. The selection criteria for healthy individuals are follows.\n\n   * women aged 18-45.\n\n     * Basic FSH\\\u003C10IU\u002FL, and AMH is within the normal range.\n\n       * Regular menstruation.\n\n         * Agree and sign an informed consent form.\n2. The selection criteria for DOR patients are follows.\n\n   * women aged 18-45.\n\n     * For two consecutive menstrual cycles, 25 ≥ basal FSH ≥ 10IU\u002FL or AMH\\\u003C1.1ng\u002Fml.\n\n       * Agree and sign an informed consent form.\n3. Selection criteria for POI patients are follows.\n\n   * 18 ≤ females aged \\\u003C40 years old.\n\n     * Two consecutive menstrual cycles with basal FSH\\>25IU\u002FL or AMH\\\u003C1.1ng\u002Fml.\n\n       * Agree and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Patients with congenital gonadal developmental abnormalities or a family history similar to \"early menopause\".\n2. Patients with acquired organic lesions or decreased ovarian function caused by ovarian surgery.\n3. Patients who have undergone artificial cycle therapy with Western medicine or other endocrine treatments within the past three months.\n4. Patients with severe primary diseases and mental disorders such as crdiovascular, cerebrovascular, liver, kidney, and hematopoietic system.\n5. Patients during lactation or pregnancy.\n6. Patients who are allergic to the drugs used in this study or have a history of allergic reactions to traditional Chinese medicine.\n\nThose who meet any of the above 5 criteria for DOR and POI will be excluded and not included in this study. The exclusion criteria for healthy subjects are as (1), (3), (4), and (5).",{"count":256,"type":21},35,"The goal of this observational study is to find differences in serum biomarkers between ovarian function and normal individuals.",[259,260,27,261,262,25],"Premature Ovarian Insufficiency","Diminished Ovarian Reserve","Copper","Ceruloplasmin","2024-12-04",{"date":265,"type":43},"2024-12-09",{"date":267,"type":43},"2023-10-25",{"date":269,"type":21},"2025-11-11",{"name":271,"class":50},"Shi Yun",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":279,"targetDuration":281,"studyType":22,"phases":4,"briefSummary":282,"conditions":283,"keywords":286,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":51},"100563278","serum-calprotectin-in-surgical-septic-patients-100563278","NCT06614088","Serum Calprotectin in Surgical Septic Patients","Serum Calprotectin in Surgical Septic Patients as an Early Predictor of Clinical Severity and Mortality: a Prospective Comparative Study.","Inclusion Criteria:\n\n* diagnosis of upper\u002Flower gastro-intestinal perforation\n* diagnosis of intestinal occlusion\n* diagnosis of acute cholecystitis\n* diagnosis of complicated acute appendicitis\n* radiological diagnosis of intra-abdominal sepsis\n\nExclusion Criteria:\n\n* recent (\\\u003C3 months) surgery\n* recent (\\\u003C3 months) trauma\n* diagnosis of acute pancreatitis\n* diagnosis of burn",{"count":280,"type":21},150,"6 Months","To early evaluate the serum levels of calprotectin in patients suffering from intra-abdominal sepsis requiring a surgical treatment. The research project aims to investigate the role of serum calprotectin in the diagnosis of sepsis and to establish whether its level significantly correlates with different degree of disease severity and with short and long-term outcomes. If these associations were confirmed, serum calprotectin would represent an easily and rapidly detectable biomarker able to predict the severity of sepsis.",[284,285,27],"Infection, Intraabdominal","Sepsis Abdominal",[287,288],"Serum calprotectin","Surgical infections","2024-09-24",{"date":291,"type":43},"2024-09-26",{"date":293,"type":43},"2021-11-01",{"date":295,"type":21},"2025-01-01",{"name":297,"class":50},"Azienda Ospedaliero, Universitaria Pisana",{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":17,"minAge":305,"maxAge":306,"enrollmentInfo":307,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":51},"100516615","prognostic-markers-of-acute-heart-failure-with-chronic-kidney-disease-100516615","NCT06006819","Prognostic Markers of Acute Heart Failure With Chronic Kidney Disease","Plasma Proteomic Signature and the Prognosis of Acute Heart Failure With or Without Chronic Kidney Disease","Inclusion Criteria:\n\n* hospitalized for acute heart failure\n\nExclusion Criteria:\n\n* initial serum NT-proBNP level \\\u003C300ng\u002Fml, pregnancy, amputated, and end-stage renal disease under regular dialysis","20 Years","90 Years",{"count":308,"type":21},155,"Acute heart failure (AHF) is defined as new or worsening of symptoms and signs of heart failure and is the most frequent cause of unplanned hospital admission in elderly patients. N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is one of the most developed prognostic markers for AHR patients and. NT-pro-BNP has limitations in terms of diagnostic or predictive accuracy in patients with chronic kidney disease (CKD). Plasma proteomics have the potential to examine underlying pathophysiological and prognostic roles, so we compared the plasma proteomic signature to predict outcomes of patients with or without CKD hospitalized for AHF.",[311,312,27],"Chronic Kidney Diseases","Acute Heart Failure","2024-08-21",{"date":315,"type":43},"2024-08-23",{"date":317,"type":43},"2023-01-01",{"date":319,"type":21},"2025-12-23",{"name":321,"class":50},"Cheng-Hsin General Hospital",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":329,"targetDuration":331,"studyType":22,"phases":4,"briefSummary":332,"conditions":333,"keywords":335,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":346},"100537304","plasma-and-tissue-saa1-levels-in-cancer-patients-to-predict-hyperprogression-of-immunotherapy-100537304","NCT06276088","Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy","A Prospective Cohort Study of Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy","Inclusion Criteria:\n\n1. Over 18 years of age\n2. Voluntarily sign informed consent\n3. The pathological diagnosis was nasopharyngeal carcinoma, head and neck tumor, lung cancer, breast cancer, stomach cancer, colorectal cancer, glioma, esophageal cancer, liver cancer, bile duct cancer, cervical cancer, prostate cancer, bladder cancer and other malignant tumors\n4. Need to be treated with immune checkpoint inhibitors\n5. ECOG PS Score: 0\u002F1.\n\nExclusion Criteria:\n\n1. There are contraindications to immunotherapy\n2. Combined with other tumors (basal cell or squamous cell skin cancer that has been cured, and cervical cancer in situ removed) External)\n3. Patients had any serious coexisting medical conditions that could pose an unacceptable risk or negatively affect trial adherence. For example, unstable heart disease requiring treatment, chronic hepatitis, kidney disease, poor disease status, uncontrolled diabetes (fasting blood glucose \\> 1.5 × ULN), and mental illness.\n4. At the investigator's discretion, those who was not considered to be suitable for participation in the study.",{"count":330,"type":21},374,"3 Years","Immune checkpoint inhibitors have ushered in a new era of cancer treatment, bringing significant survival benefits to patients. However, some patients have accelerated tumor growth in the early stage of immunotherapy, called hyperprogression. The quality of life of patients with hyperprogression is seriously reduced, and there is no effective treatment at present, and the prognosis is extremely poor. Therefore, early identification of high-risk groups of hyperprogression is the key to prevent hyperprogression. However, there are no effective biomarkers to predict hyperprogression. By sequencing, proteomics and metabolomics analysis of clinical tissue and blood samples, we found that the level of SAA1 was significantly increased in patients with hyperprogression, and SAA1 was an effective marker for predicting hyperprogression in pan-cancer. We planned to conduct a multicenter, prospective cohort study to verify the reliability of SAA1 as a marker for predicting hyperprogression of immunotherapy in pan-cancer patients.",[211,334,27],"Hyperprogression",[336,211,334,337],"SAA1","Pan-cancer","2024-03-13",{"date":340,"type":43},"2024-03-15",{"date":342,"type":43},"2024-02-18",{"date":344,"type":21},"2026-10-31",{"name":199,"class":50},5,{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":356,"conditions":357,"keywords":361,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":346},"100539705","plasma-saa1-levels-in-predicting-response-to-radiotherapy-induced-oral-mucositis-100539705","NCT06307314","Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis","A Prospective Cohort Study of Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis","Inclusion Criteria:\n\n* Over 18 years of age.\n* Voluntarily sign informed consent.\n* The pathological diagnosis was nasopharyngeal carcinoma, head and neck tumor.\n* Need to be treated with radiotherapy.\n* ECOG PS Score: 0\u002F1.\n\nExclusion Criteria:\n\n* There are contraindications to radiotherapy.\n* Combined with other tumors.\n* Patients had any serious coexisting medical conditions that could pose an unacceptable risk or negatively affect trial adherence. For example, unstable heart disease requiring treatment, chronic hepatitis, kidney disease, poor disease status, uncontrolled diabetes (fasting blood glucose \\> 1.5 × ULN), and mental illness.\n* At the investigator's discretion, those who was not considered to be suitable for participation in the study.",{"count":355,"type":21},300,"Head and neck squamous cell carcinoma (SCC) is the sixth most common cancer worldwide, with more than 700,000 new cases and more than 350,000 deaths each year. At present, radiotherapy is an important measure to control the recurrence of head and neck tumors, but almost all patients with head and neck squamous cell carcinoma will have acute inflammatory reactions such as radiotherapy-induced oral mucositis (RIOM) after radiotherapy, which seriously affects the quality of life and radiotherapy efficacy of patients. Serum amyloid A1 (SAA1) is an acute phase protein associated with inflammation. Our previous basic research found that serum SAA1 expression levels can be used as biomarkers to assess the dose received by the receptor in the early stages of radiation damage. At the same time, we confirmed that the serum level of SAA1 in patients with nasopharyngeal carcinoma increased after radiotherapy. Therefore, we intend to conduct a prospective, multicenter, observational study to further explore the predictive power of plasma SAA1 levels for radiotherapy-induced oral mucositis, with a view to early screening and prevention of RIOM patients.",[358,359,360,27],"Nasopharyngeal Carcinoma","Head and Neck Cancer","Radiotherapy-induced Oral Mucositis",[336,360,359,358],"2024-03-06",{"date":364,"type":43},"2024-03-12",{"date":366,"type":43},"2024-02-01",{"date":368,"type":21},"2026-12-31",{"name":199,"class":50},{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":377,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":400},"100497984","imapct-of-biomarkers-on-pharmacodynamics-and-bleeding-risk-of-direct-oral-anticoagulants-and-ticagrelor-study-ii-100497984","NCT05764356","Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II","Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II (IMPACT 2)","Inclusion Criteria:\n\n(I) Chinese Patients taking NOACs\n\n* In accordance with anticoagulation indications of NOACs, include prevention of thrombosis in non valvular atrial fibrillation, prevention and treatment of deep vein thrombosis \u002F pulmonary embolism and prevention of thrombosis after knee \u002F hip replacement;\n* More than 18 years of age, male or female;\n* Never received NOACs in a month and intend to take NOACs or have received NOACs for more than one week continuously;\n* sign informed consent.\n\n(II) Chinese Patients taking ticagrelor\n\n* With diagnosis of acute coronary syndrome (ACS), included unstable angina, non ST segment elevation myocardial infarction and ST segment elevation myocardial infarction;\n* More than 18 years of age, male or female;\n* Never received ticagrelor in a month and intend to take ticagrelor or have received ticagrelor for more than one week continuously#\n* sign informed consent.\n\nExclusion Criteria:\n\n* With history of immunodeficiency disease, including positive HIV index;\n* Positive Hepatitis B surface antigen (HBsAg) and HCV index;\n* Combined therapy of CYP3A4 strong inhibitors and P-gp inhibitors (e.g., systemic pyrrole antifungal agents such as ketoconazole, itraconazole, voriconazole and posaconazole; human immunodeficiency virus (HIV) - protease inhibitors such as ritonavir), CYP3A4 strong inducers and P-gp inducers (e.g., rifampicin, phenytoin, phenobarbital, carbamazepine, St. John's Wort, etc.) in 14 days before treatment with NOACs;\n* Severe liver dysfunction and abnormal renal function;\n* Include contraindications of antithrombosis, such as hypersensitivity, active bleeding, moderate or severe liver disease, previous history of intracranial hemorrhage, gastrointestinal hemorrhage in the past 6 months and major operation within 30 days.",{"count":378,"type":21},2000,"Individual differences in drug efficacy and adverse reactions are common in the clinical application of drugs. Individual differences are caused by many factors, among which genetic factors account for more than 20%. Novel oral anticoagulant drugs (NOACs, including rivaroxaban, apixaban, edoxaban, dabigatran, etc.) and novel antiplatelet drug ticagrelor have the advantages of convenient use and no need for monitoring. But novel oral antithrombotic drugs also increase the risk of bleeding, and there is currently a lack of effective antagonists when antithrombosis is excessive or emergency surgery is required. At present, there are few studies on the causes of individual differences in novel antithrombotic drugs, and there is a lack of predictable biomarkers or drug genotypes, especially in China. Therefore, on the basis of previous studies on NOACs and ticagrelor individualized medication cohorts, this study plans to establish a validation cohort for novel antithrombotic drugs bleeding related biomarkers, conduct multi-omics testing and long-term follow-up, and explore markers related to pharmacodynamics of antithrombotic drugs, adverse bleeding reactions and clinical outcomes.",[381,382,383,384,385,386,387,388,389,390,391,27],"Novel Oral Anticoagulants","NOACs","Rivaroxaban","Apixaban","Edoxaban","Dabigatran","Ticagrelor","Pharmacodynamics","Pharmacogenomics","RNA Profile","Bleeding","2023-03-01",{"date":394,"type":43},"2023-03-10",{"date":396,"type":21},"2023-03",{"date":398,"type":21},"2027-12",{"name":143,"class":50},6,{"id":402,"slug":403,"hasResults":11,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":408,"targetDuration":410,"studyType":22,"phases":4,"briefSummary":411,"conditions":412,"keywords":415,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":421,"leadSponsor":423,"locationsCount":4},"100497103","a-novel-biomarker-for-response-and-prognosis-of-hbv-related-hepatocellular-carcinoma-100497103","NCT05752890","A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma","Developing a Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma Treated With Radiotherapy: Personalized Cell-free Virus-host Chimera DNA","Inclusion Criteria:\n\n1. Patients diagnosed with HCC by dynamic image criteria and\u002For biopsy\n2. HBsAg (+)\n3. Child-Turcotte-Pugh (CTP) class A-B liver function\n4. Radiotherapy to liver tumor as the main treatment\n\nExclusion Criteria:\n\n1. Child-Turcotte-Pugh (CTP) class C liver functiECOG performance status score \\>2\n2. Has had prior radiotherapy to the proposed treatment field.\n3. \\\u003C 18 years old",{"count":409,"type":21},95,"3 Months","The investigators will first use our previously collected serum samples and surgical\u002Fbiopsied tissues from HBV-related HCC patients undergoing radiotherapy. The consistency of junctional clones by Capture NGS needs to be tested between both pre- and post-RT serums, and serial changes in copy numbers of vh-DNA by ddPCR are quantified in the representative cases. The same junction clones from pre-post-RT serums and surgical tissues will be confirmed and the copy number changes of vh-DNA be correlated with RT response and disease-control status.\n\nThe investigators plan to identify HBV integrations by Capture NGS and quantify the specific vh-DNA by ddPCR as personalized biomarkers from the same-patient serum samples. The investigators will further correlate clinical response and recurrence\u002Fmetastasis with serial changes of vh-DNA copy numbers. The investigators have been prospectively collecting plasma samples from HBV-related HCC patients before\u002Fafter RT, at 1, 4, 7 months, and at recurrence\u002Fmetastasis. The investigators plan to confirm the viable role of pre-\u002Fpost-RT changes of plasma vh-DNA copies of the same junction clone in post-RT response and prognosis. Moreover, The investigators will explore the recurrent\u002Fmetastatic tumors arising from the original or a de novo one by identifying their clonality with HBV integration patterns. The true value of this novel HBV chimera vh-DNA will be revealed. The results will also support the consolidative use of personalized vh-DNA for earlier evaluating treatment response after RT, for post-RT disease monitoring, and for differentiating clonality at recurrence to design future clinical trial on combinational treatment.",[413,414,187,27],"Hepatocellular Carcinoma","Hepatitis b Virus",[413,414,187,416,27],"Chimera DNA","2023-02-21",{"date":419,"type":43},"2023-03-03",{"date":392,"type":21},{"date":422,"type":21},"2031-01-31",{"name":424,"class":50},"National Taiwan University Hospital",{"id":426,"slug":427,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":16,"sex":17,"minAge":59,"maxAge":90,"enrollmentInfo":431,"targetDuration":432,"studyType":22,"phases":4,"briefSummary":433,"conditions":434,"keywords":436,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":444,"locationsCount":51},"100434008","screening-and-application-research-of-early-diabetic-nephropathy-markers-based-on-lipidomics-100434008","NCT04931537","Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.","Inclusion Criteria:\n\n1. Subjects who have signed informed consent.\n2. Subjects were 20-80 years old and of either gender.\n3. Subjects showed good compliance, and the follow-up data was available for \\>5 years.\n\nExclusion Criteria:\n\n1. Meet the 1999 World Health Organization (WHO) diagnostic criteria for T1DM、T2DM;\n2. Renal diseases caused by other causes, including primary and secondary;\n3. All kinds of acute infections;\n4. The expected life expectancy (life expectancy or related diseases) was less than 5 years according to the researcher's judgment.\n5. Drug users or drug abusers;\n6. Sexually transmitted diseases such as viral hepatitis, AIDS and syphilis, and infectious diseases such as tuberculosis are in an active period;\n7. Any situation judged by the researcher that affects enrollment.",{"count":20,"type":21},"5 Years","Diabetic nephropathy (DN) is one of the major microvascular complications associated with diabetic patients, and also the major global cause of chronic kidney disease and end-stage renal disease (ESRD). Albuminuria and estimated glomerular filtration rate (eGFR) are currently recognized clinical indicators for early diagnosis of DN, however, the sensitivity and specificity are unsatisfactory. The early identification and treatment of DKD are conducive to lowering the risk of kidney damage by as much as 50%. Therefore, it is particularly critical to find new biomarkers to reflect the potential DKD lesions in the clinical silent period earlier and more accurately. Therefore, this study intends to analyze the differentially expressed lipids in early DKD, T2DM and healthy adults by mass spectrometry, and verify the related results by larger samples, so as to screen out early markers of DKD and achieve the ultimate goal of clinical application.",[435,27],"Diabetic Nephropathy Type 2",[435,437],"Metabonomics","2021-07-14",{"date":440,"type":43},"2021-07-20",{"date":442,"type":43},"2021-05-01",{"date":197,"type":21},{"name":445,"class":50},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]